Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.17
DVAX's Cash-to-Debt is ranked lower than
71% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. DVAX: 2.17 )
Ranked among companies with meaningful Cash-to-Debt only.
DVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.17  Med: No Debt Max: No Debt
Current: 2.17
2.17
No Debt
Equity-to-Asset 0.50
DVAX's Equity-to-Asset is ranked lower than
72% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. DVAX: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
DVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.28  Med: 0.76 Max: 0.94
Current: 0.5
-2.28
0.94
Debt-to-Equity 0.76
DVAX's Debt-to-Equity is ranked lower than
78% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. DVAX: 0.76 )
Ranked among companies with meaningful Debt-to-Equity only.
DVAX' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.14  Med: 0.24 Max: 1.94
Current: 0.76
-7.14
1.94
Debt-to-EBITDA -0.85
DVAX's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. DVAX: -0.85 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DVAX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.01  Med: -0.25 Max: -0.11
Current: -0.85
-1.01
-0.11
Piotroski F-Score: 1
Altman Z-Score: -2.48
Beneish M-Score: -6.12
WACC vs ROIC
2.37%
-999.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -8485.80
DVAX's Operating Margin % is ranked lower than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. DVAX: -8485.80 )
Ranked among companies with meaningful Operating Margin % only.
DVAX' s Operating Margin % Range Over the Past 10 Years
Min: -28508.26  Med: -639.29 Max: -37.49
Current: -8485.8
-28508.26
-37.49
Net Margin % -8570.06
DVAX's Net Margin % is ranked lower than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. DVAX: -8570.06 )
Ranked among companies with meaningful Net Margin % only.
DVAX' s Net Margin % Range Over the Past 10 Years
Min: -29099.08  Med: -656.55 Max: -56.15
Current: -8570.06
-29099.08
-56.15
ROE % -76.01
DVAX's ROE % is ranked lower than
66% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. DVAX: -76.01 )
Ranked among companies with meaningful ROE % only.
DVAX' s ROE % Range Over the Past 10 Years
Min: -307.22  Med: -70.1 Max: -49.94
Current: -76.01
-307.22
-49.94
ROA % -55.74
DVAX's ROA % is ranked lower than
67% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. DVAX: -55.74 )
Ranked among companies with meaningful ROA % only.
DVAX' s ROA % Range Over the Past 10 Years
Min: -85.08  Med: -52 Max: -19.74
Current: -55.74
-85.08
-19.74
ROC (Joel Greenblatt) % -760.62
DVAX's ROC (Joel Greenblatt) % is ranked lower than
55% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. DVAX: -760.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1090.64  Med: -757.59 Max: -172.67
Current: -760.62
-1090.64
-172.67
3-Year Revenue Growth Rate -75.70
DVAX's 3-Year Revenue Growth Rate is ranked lower than
88% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. DVAX: -75.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -31.1 Max: 88.2
Current: -75.7
0
88.2
3-Year EBITDA Growth Rate 20.20
DVAX's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. DVAX: 20.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.1  Med: 12.4 Max: 63.3
Current: 20.2
-39.1
63.3
3-Year EPS without NRI Growth Rate 19.30
DVAX's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. DVAX: 19.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.3  Med: 18.6 Max: 60.6
Current: 19.3
-26.3
60.6
GuruFocus has detected 5 Warning Signs with Dynavax Technologies Corp DVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVAX's 30-Y Financials

Financials (Next Earnings Date: 2018-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

DVAX Guru Trades in Q3 2017

Jim Simons 89,551 sh (New)
John Paulson Sold Out
Steven Cohen 1,110,628 sh (-18.40%)
» More
Q4 2017

DVAX Guru Trades in Q4 2017

Paul Tudor Jones 10,271 sh (New)
Steven Cohen 3,808,142 sh (+242.88%)
Jim Simons 82,051 sh (-8.38%)
» More
Q1 2018

DVAX Guru Trades in Q1 2018

Ken Fisher 88,523 sh (New)
John Hussman 75,000 sh (New)
Jim Simons 228,919 sh (+179.00%)
Steven Cohen 5,063,934 sh (+32.98%)
Paul Tudor Jones Sold Out
» More
Q2 2018

DVAX Guru Trades in Q2 2018

John Hussman 75,000 sh (unchged)
Jim Simons Sold Out
Ken Fisher 70,270 sh (-20.62%)
Steven Cohen 1,455,034 sh (-71.27%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:DVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -20.62%$15.15 - $20.75 $ 12.00-31%70,270
Ken Fisher 2018-03-31 New Buy$14.65 - $19.9 $ 12.00-31%88,523
John Paulson 2017-09-30 Sold Out 0.07%$9 - $21.25 $ 12.00-23%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:TGTX, SZSE:002022, NYSE:BHVN, NAS:PTCT, TSXV:CRON, OSTO:HMED, SHSE:603718, XKRX:003000, ASX:SRX, NAS:ACOR, SHSE:603896, SHSE:600200, NYSE:CO, NAS:RGNX, XPAR:ALCLS, NAS:ADAP, SAU:2070, SZSE:002872, NAS:RVNC, SZSE:300204 » details
Traded in other countries:DYF1.Germany,
Headquarter Location:USA
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.

Top Ranked Articles about Dynavax Technologies Corp

Dynavax Announces Publication of Preclinical Study of TLR9 Agonist in Lung Cancer
Dynavax Announces Publication of Two Papers in Leading Oncology Journal Highlighting Data From Clinical Studies of Its TLR9 Agonist, SD-101
Consolidated Research: 2018 Summary Expectations for National Instruments, Dynavax Technologies, BWX Technologies, Fossil Group, GCP Applied Technologies, and Stratasys — Fundamental Analysis, Key Performance Indications
Dynavax Reports Second Quarter 2018 Financial Results
Dynavax to Host Second Quarter 2018 Financial Results Conference Call
Dynavax Appoints Scientific Advisory Board to Support its Oncology and Vaccine Programs
Dynavax Presents Analysis of Data for Participants Aged 60 to 70 with Diabetes from its Phase 3 Trial of HEPLISAV-B®
Dynavax to Present at the William Blair 38th Annual Growth Stock Conference
Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting

Ratios

vs
industry
vs
history
PB Ratio 5.72
DVAX's PB Ratio is ranked lower than
66% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. DVAX: 5.72 )
Ranked among companies with meaningful PB Ratio only.
DVAX' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 4.83 Max: 14.94
Current: 5.72
0.65
14.94
PS Ratio 500.02
DVAX's PS Ratio is ranked lower than
94% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DVAX: 500.02 )
Ranked among companies with meaningful PS Ratio only.
DVAX' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 26.64 Max: 3308.33
Current: 500.02
0.18
3308.33
EV-to-EBIT -5.01
DVAX's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. DVAX: -5.01 )
Ranked among companies with meaningful EV-to-EBIT only.
DVAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.2  Med: -3.75 Max: 6.3
Current: -5.01
-26.2
6.3
EV-to-EBITDA -5.41
DVAX's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. DVAX: -5.41 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.3  Med: -3.7 Max: 32.5
Current: -5.41
-16.3
32.5
EV-to-Revenue 425.39
DVAX's EV-to-Revenue is ranked lower than
91% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. DVAX: 425.39 )
Ranked among companies with meaningful EV-to-Revenue only.
DVAX' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.6  Med: 20.5 Max: 3122.3
Current: 425.39
-1.6
3122.3
Current Ratio 8.87
DVAX's Current Ratio is ranked higher than
73% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. DVAX: 8.87 )
Ranked among companies with meaningful Current Ratio only.
DVAX' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 6.2 Max: 15.29
Current: 8.87
1.87
15.29
Quick Ratio 8.67
DVAX's Quick Ratio is ranked higher than
73% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. DVAX: 8.67 )
Ranked among companies with meaningful Quick Ratio only.
DVAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 6.2 Max: 15.29
Current: 8.67
1.87
15.29
Days Inventory 43.19
DVAX's Days Inventory is ranked higher than
79% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. DVAX: 43.19 )
Ranked among companies with meaningful Days Inventory only.
DVAX' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 43.19
Current: 43.19
0
43.19
Days Sales Outstanding 318.79
DVAX's Days Sales Outstanding is ranked lower than
97% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. DVAX: 318.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.1  Med: 37.76 Max: 318.79
Current: 318.79
8.1
318.79
Days Payable 119.80
DVAX's Days Payable is ranked higher than
67% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. DVAX: 119.80 )
Ranked among companies with meaningful Days Payable only.
DVAX' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 119.8
Current: 119.8
0
119.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.70
DVAX's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. DVAX: -32.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -180.4  Med: -31.5 Max: -9.4
Current: -32.7
-180.4
-9.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.02
DVAX's Price-to-Net-Cash is ranked lower than
61% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. DVAX: 9.02 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DVAX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.85  Med: 5.24 Max: 32.5
Current: 9.02
1.85
32.5
Price-to-Net-Current-Asset-Value 8.00
DVAX's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. DVAX: 8.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DVAX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.79  Med: 4.77 Max: 124
Current: 8
1.79
124
Price-to-Tangible-Book 6.67
DVAX's Price-to-Tangible-Book is ranked lower than
64% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. DVAX: 6.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DVAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.73  Med: 4.51 Max: 27.68
Current: 6.67
1.73
27.68
Price-to-Median-PS-Value 18.75
DVAX's Price-to-Median-PS-Value is ranked lower than
99% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. DVAX: 18.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.83 Max: 124.06
Current: 18.75
0.02
124.06
Earnings Yield (Greenblatt) % -19.98
DVAX's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. DVAX: -19.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14882  Med: -23.3 Max: 3563.3
Current: -19.98
-14882
3563.3

More Statistics

Revenue (TTM) (Mil) $1.49
EPS (TTM) $ -2.09
Beta-0.10
Volatility42.08%
52-Week Range $11.35 - 24.45
Shares Outstanding (Mil)62.62

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -2.42 -1.70
EPS without NRI ($) -2.42 -1.70
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}